1[1]Kibbler CC.Infections in liver transplantation:risk factors and strategies for prevention[J].J Hosp Infect,1995,30(suppll):209-17.
2[2]Echaniz A.Pita S.Otero A.et al.Incidence,risk factors and influence on survival of infectious complications in live transplantation[J].Enfermedades Infecciosas y Microbiologia Clinica.2003,21(5):224-31.
3[3]Carlos V,Paya.Prevention of Fungal infection and Heoatitis Virus Infections in Liver Transplantation.CliInfectDis,2001,33(auppll):s47-52.
4[5]Jay A,Rubin RH.Infection in organ transplantation recipients:N Engl Med,1998,338:1741-1749.
5[6]Halme L.Hockerstedt K.Lauatenschlager I.Cytomegalovirus infection and development of biliary complications after liver transplantation[J].[Journal Article]Transplantation.2003,75(11):1853-8.
6[7]Longinov R.Hockerstedt K.Lautenschlager I.Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment[J].Archives of Virology.2003,148(7):1269-74.
8[9]Lo CM.Fan ST.Liu CL.Lai CL.Wong J.Prophylaxis and treatment of recurrent hepatitis B after liver transplantation[J].[Review][30 refs][Journal Article.Review.Review,Tutoria]Transplantation.2003,75(3Suppl):S41-4.
9[10]Shouval D,Samuel D.Hepatitis B immune globuin to prevent hepatitis B virus graft reifection following liver transplantation:A concise review.Hepatology 2000,32:1189.
2Jain A, Demetris AJ, Manez R, et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alpha interferon. Liver Transpl Surg, 1998, 4: 197-203.
3Nour B, Tzakis A, Van Thiel DH. The use of interferon for the treatment of viral hepatitis in pediatric liver transplant recipients. J Okla State Med Assoc, 1995, 88: 109-113.
4Perrillo R, Rakela J, Dienstag J, et al. Multicenter study for lamivudine therapy of hepatitis B after liver transplantation. Hepatology, 1999, 29: 1581-1586.
5McCaughan GW. Indications for liver transplantation for chronic viral hepatitis, and therapies for controlling hepatitis B virus infection before and after transplantation. J Gastroenterol Hepatol, 2000, 15(suppl): E172-E174.
6Perrillo R, Schiff E, Yoshida E, et al. Adefovir Dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology, 2000, 32: 129-134.
7Angus PW. Review: hepatitis B and transplantation. J Gastroenterol Hepatol, 1997, 12: 217-223.
8Samuel D, Bismuth H, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet, 1991, 337: 812-815.
9Nymann T, Shokouh-Amiri MH, Vera SR, et al. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIg) prophylaxis after liver transplantation. Clin Transplant, 1996, 10: 663-667.
10McCory RW, Ishitani MB, Oliverira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immuniazation. Transplantation, 1996, 61: 1358-1364.
